Core Points - On November 19, Angli康's stock dropped by 5.16%, trading at 40.47 CNY per share, with a transaction volume of 484 million CNY and a turnover rate of 6.31%, resulting in a total market capitalization of 8.164 billion CNY [1] - Angli康, established on December 30, 2001, and listed on October 23, 2018, is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main revenue sources being formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Shareholder Analysis - Among Angli康's top ten circulating shareholders, a fund under China Europe Fund holds a significant position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 3.351 million shares in the third quarter, now holding 3.0863 million shares, which accounts for 1.67% of the circulating shares. The estimated floating loss today is approximately 6.7899 million CNY [2] - The China Europe Medical Health Mixed A Fund (003095) was established on September 29, 2016, with a current scale of 16.977 billion CNY. Year-to-date returns are 20.05%, ranking 4065 out of 8138 in its category; the one-year return is 16.2%, ranking 4684 out of 8055; and since inception, the return is 107.2% [2] Fund Manager Information - The fund managers of the China Europe Medical Health Mixed A Fund (003095) are Ge Lan and Zhao Lei. As of the report, Ge Lan has a cumulative tenure of 10 years and 298 days, with the fund's total asset scale at 43.544 billion CNY, achieving the best return of 107.89% and the worst return of -35.13% during her tenure [3] - Zhao Lei has a cumulative tenure of 139 days, with the fund's total asset scale at 32.954 billion CNY, achieving the best return of 8.11% and the worst return of 7.8% during his tenure [3]

截至发稿，葛兰累计任职时间10年293天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 109.26%， 任职期间最差基金回报-35.13%。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）三季度 增持397.67万股，持有股数1740.3万股，占流通股的比例为1.96%。根据测算，今日浮盈赚取约1879.52 万元。连续4天上涨期间浮盈赚取1583.67万元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益24.47%， 同类排名3925/8140；近一年收益13.31%，同类排名4906/8056；成立以来收益114.81%。 11月14日，九洲药业涨5.31% ...

资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 截至发稿，葛兰累计任职时间10年292天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 107.34%， 任职期间最差基金回报-35.13%。 赵磊累计任职时间133天，现任基金资产总规模329.54亿元，任职期间最佳基金回报7.83%， 任职期间 最差基金回报7.52%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 11月13日，广生堂涨5.03%，截至发稿，报109.55元/股，成交8.12亿元，换手率5.70%，总市值174.48亿 元。 从广生堂十大流通股东角度 数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（0 ...

赵磊累计任职时间131天，现任基金资产总规模329.54亿元，任职期间最佳基金回报7.72%， 任职期间 最差基金回报7.43%。 数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约424.18万 元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益21.33%， 同类排名4326/8147；近一年收益10.73%，同类排名5278/8056；成立以来收益109.4%。 中欧医疗健康混合A（003095）基金经理为葛兰、赵磊。 截至发稿，葛兰累计任职时间10年290天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 107.15%， 任职期间最差基金回报-35.13%。 11月11日，广生堂涨5.82%，截至发稿，报108.92元/股，成交9.16亿元，换手率6.61%，总市值173.47亿 元。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新 ...

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.09% to 102.88 CNY per share, with a trading volume of 722 million CNY and a turnover rate of 5.01%, resulting in a total market capitalization of 16.385 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.909 million CNY. The fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY, and has achieved a year-to-date return of 21.69% [2] - The fund's one-year return is 13.44%, ranking 5002 out of 8053 in its category, while since its inception, it has achieved a return of 110.03% [2]

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.03% to 113.01 CNY per share, with a trading volume of 925 million CNY and a turnover rate of 5.80%, resulting in a total market capitalization of 17.999 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company primarily focuses on the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a current scale of 16.977 billion CNY. Year-to-date returns are 25.14%, ranking 3731 out of 8150 in its category, while the one-year return is 20.3%, ranking 4361 out of 8043 [2]

Group 1 - Core viewpoint: Huadong Medicine (000963.SZ) reported its Q3 2025 results, highlighting significant institutional ownership and changes in shareholding among various funds and investors [1][2][3] Group 2 - As of October 27, 2025, 32 institutional investors held a total of 1.205 billion shares of Huadong Medicine, representing 68.71% of its total share capital [1] - The top ten institutional investors collectively held 67.93% of the shares, with an increase of 0.71 percentage points compared to the previous quarter [1] - In the public fund sector, 10 funds increased their holdings, while 8 funds reduced their holdings, with a decrease of 0.50% in the latter category [2] - One social security fund, the National Social Security Fund 112 Portfolio, reported a slight decrease in holdings [2] - In the insurance sector, one insurance company increased its holdings by 0.3%, while one new insurance investor was disclosed [3] - Foreign investment saw an increase from one foreign fund, Hong Kong Central Clearing Limited, with a rise of 0.69% in holdings [3]

Core Insights - Angli康 (002940.SZ) reported its Q3 2025 results, revealing that as of October 24, 2025, nine institutional investors held a total of 94.36 million shares, representing 46.77% of the company's total equity [1] - The institutional holding percentage decreased by 7.00 percentage points compared to the previous quarter [1] Institutional Holdings - The institutional investors include Shenzhou JunTai Investment Co., Ltd., Zhejiang Angli康 Pharmaceutical Co., Ltd. - Phase I Employee Stock Ownership Plan, and several funds from major banks such as Bank of China, Industrial and Commercial Bank of China, and China Construction Bank [1] - The total institutional holding percentage is now at 46.77%, down from the previous quarter [1] Public Fund Holdings - Four public funds increased their holdings this period, including Huatai-PB Innovation Medicine Mixed A, GF Healthcare Stock A, and others, with an increase rate of 1.45% [2] - One public fund, China Europe Medical Health Mixed A, reported a decrease in holdings by 1.66% compared to the previous quarter [2] - One new public fund was disclosed this period, namely Longcheng Pharmaceutical Industry Selected Mixed Initiation A [2] - A total of 114 public funds were not disclosed this period, including notable funds like GF Technology Innovation Mixed A and others [2]

Group 1 - The core point of the news is that Lizhu Group (000513.SZ) reported its Q3 2025 results, highlighting significant institutional investor interest with a total of 3.02 billion shares held by 10 institutions, representing 33.44% of the total share capital [1] - The top ten institutional investors include Health元药业集团股份有限公司, Hong Kong Central Clearing Limited, and others, with their combined holding ratio increasing by 0.01 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, there was a slight increase in holdings from one public fund, while two public funds reduced their holdings by 0.27% [2] - The social security fund saw an increase in holdings from one fund, while one pension fund was no longer disclosed [2] - Foreign investment sentiment showed an increase in holdings from one foreign fund, with a rise of 0.33% [2]

Core Insights - The A-share market in the first half of 2025 exhibited a volatile pattern influenced by policy and fundamentals, while the public fund industry presented a noteworthy semi-annual performance report [2] - The top ten fund managers by management scale are predominantly leaders of index products, with Liu Jun from Huatai-PB Fund leading at a scale of 4120.1 billion yuan, which increased to 4669.8 billion yuan by the end of September [2][4] - Zhang Wei from Huitianfu Fund emerged as a standout performer, with his managed fund achieving an impressive 86.48% return, significantly outperforming the market, and a year-to-date return of 159% [2][24] Group 1: Fund Management Scale - The competition for management scale in the public fund industry has shifted, with the managers of the CSI 300 ETF holding a dominant position [3] - The top fund managers by management scale include Liu Jun (4120.09 billion yuan), Yu Haiyan (3219.50 billion yuan), and Pang Yaping (2568.34 billion yuan) [4] - The CSI 300 ETF reached a scale of over 1000 billion yuan in August 2023, surpassed 3000 billion yuan in September 2024, and exceeded 4000 billion yuan shortly thereafter [8] Group 2: Performance of Fund Managers - Zhang Wei from Huitianfu Fund achieved a remarkable 47.93% return in the first half of 2025, followed by Zhang Lu from Yongying Fund with 33.88% and Tian Ximeng from Fuquo Fund with 25.18% [16][17] - The average return of the top fund managers over the past three months was 29.5%, with the highest being Du Meng from Morgan Fund at 62.4% [18] - The performance of the CSI 300 index has been consistent, with major index funds showing similar returns, reflecting the nature of index funds to track their benchmark closely [10] Group 3: Sector Insights - The CSI 300 index serves as a key indicator of the overall performance of the A-share market, encompassing the largest and most liquid 300 stocks, representing major industries in the Chinese economy [11] - The top ten weighted stocks in the CSI 300 index include Kweichow Moutai, Ningde Times, and China Ping An, collectively accounting for over 20% of the index [12] - High-dividend sectors such as banking and non-bank financials are significant contributors to the index, with the potential for increased dividend yields [13] Group 4: Notable Fund Strategies - Zhang Wei's success is attributed to the strong rebound in the innovative pharmaceutical sector, with his fund's performance benefiting from this trend [24][28] - Zhang Lu's rapid rise in performance was linked to a strategic shift towards humanoid robotics, which capitalized on market trends [43][49] - The overall trend indicates that deep research and strategic positioning are crucial for achieving excess returns in a structural market [51]